| Name | 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine |
|---|---|
| Synonyms |
MFCD00823171
1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine 1-(3,4-dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol sulfate (salt) Tobra Gobens Tomycin 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- 5-aethyl-1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4-methyl-5H-benzodiazepin (1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (salt) Dicon Egyt 341 EINECS 244-922-3 (1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (1:1) Dartobcin Tofisopamum [INN-Latin] Tobracin Tofisopam [INN:DCF:JAN] Emandaxin Nebcine UNII:UZC80HAU42 Obracin Tobraneg 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine -3,5-diol sulfate (salt) -3,5-diolsulfat(salt) (2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran-3,5-diol sulfate (salt) Tobrasix Grandaxin 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine Tofisopam 1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-5-ethyl-4-methyl-5H-2,3-benzodiazepine α-D-Glucopyranoside, (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-, sulfate (1:1) (salt) 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine,EGYT 341,Seriel Trazil tofizopam Tobryne (2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran Seriel (2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diolsulfat(salt) |
| Description | Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tofisopam administration at a dose of 50 mg/kg for seven days improves the impaired cognitive performance, enhances the attenuated synaptic transmission in the hippocampus, increases proliferation in subgranular zones, and improves the decrease in astrocytes in amnesic rats[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 479.0±45.0 °C at 760 mmHg |
| Melting Point | 155-159ºC |
| Molecular Formula | C18H39N5O13S |
| Molecular Weight | 565.593 |
| Flash Point | 195.2±21.2 °C |
| Exact Mass | 565.226501 |
| PSA | 61.64000 |
| LogP | 2.39 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.558 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS07, GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H400 |
| Precautionary Statements | P273 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn: Harmful;N: Dangerous for the environment; |
| Risk Phrases | R22;R50 |
| Safety Phrases | 60-61 |
| RIDADR | UN 3077 |
| WGK Germany | 2 |
| RTECS | DE9540000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
|
~60%
22345-47-7 |
| Literature: Gatta; Piazza; Del Giudice; Massotti Farmaco, Edizione Scientifica, 1985 , vol. 40, # 12 p. 942 - 955 |
|
~95%
22345-47-7 |
| Literature: Vela Pharmaceuticals, Inc. Patent: US2006/264421 A1, 2006 ; Location in patent: Page/Page column 3 ; |
|
~%
22345-47-7 |
| Literature: US2006/264421 A1, ; Page/Page column 2 ; |
|
~%
22345-47-7 |
| Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
|
~%
22345-47-7 |
| Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
|
~%
22345-47-7 |
| Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
|
~%
22345-47-7 |
| Literature: Heterocycles, , vol. 88, # 1 p. 287 - 295 |
|
~%
22345-47-7 |
| Literature: Heterocycles, , vol. 88, # 1 p. 287 - 295 |